Celularity licenses biomaterials portfolio for up to $35M; retains manufacturing, cuts costs

Celularity Inc

Up to $35M cash: $15M upfront plus $20M milestone payments based on net sales targets.
Celularity will act as exclusive manufacturer of licensed products at its New Jersey FDA-compliant facility.
Workforce reduction and organizational realignment expected to lower operating costs and sharpen focus on longevity therapeutics.
Transaction expected to close no later than April 15, 2026, subject to customary conditions including financing.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.